Angiotensin converting enzyme inhibitors and diabetic nephropathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis.BMJ (Clinical research ed.) · 1992
   Trial
2. Renoprotective role of ACE inhibitors in diabetic nephropathy.British heart journal · 1994
   Review
3. Treatment of hypertension in the presence of coexisting medical conditions.Drugs & aging · 1994
   Review
4. Beta 2-glycoprotein-1 (apolipoprotein H) excretion and renal tubular malfunction in diabetic patients without clinical proteinuria.Journal of clinical pathology · 1993
   Article
5. Treatment of diabetes mellitus.Diabetologia · 1992
   Review
6. Renal protective effect of enalapril in diabetic nephropathy.BMJ (Clinical research ed.) · 1992
   Article

Corrections and comments

• Comment on
  Renal protective effect of enalapril in diabetic nephropathy.1992

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as